Clinical trials: Apatinib
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
The study includes the screening period (from the time the subject signs the informed consent form to no more than 28 days before the first dose, imaging evaluations are allowed within 28 days before the first dose, and 5-14 days…
- Trial name
- NCT06773156
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Metastatic Castration Resistant Prostate Cancer
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT04869488
- Testing
- Fluzoparib, Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets, Fluzoparib Combined With Apatinib
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies, Urothelial Carcinoma
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab.
- Conditions
- Advanced Malignancies, Urothelial Carcinoma, MSI-H or dMMR Solid Tumors, Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- APPEASE (NCT03407976)
- Testing
- Apatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Advanced Hepatocellular Carcinoma
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular…
- Trial name
- NCT05924997
- Testing
- adebrelimab, camrelizumab plus apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Gastric Cancer, GastroEsophageal Cancer
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as…
- Trial name
- NCT03813784
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 885 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy
- Trial name
- NCT04338438
- Testing
- Apatinib Mesylate tablets combined with S-1 capsules
- Volunteers
- 37 people
- Sponsor
- Beijing Friendship Hospital
Solid Tumor
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Apatinib and SHR-1210 are new drugs produced by jiangsu hengrui pharmaceutical co., LTD. Both are listed in China. The investigators want to design a trial to explore the efficacy and safety of Apatinib and SHR-1210 in patients…
- Trial name
- NCT04832204
- Testing
- Apatinib and Camrelizumab for Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing Hospital
Advanced Hepatocellular Carcinoma
A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.
- Trial name
- HCC (NCT01192971)
- Testing
- Apatinib
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.
- Trial name
- NCT05049681
- Testing
- Camrelizumab, Apatinib
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Feng Wang
Stage IVB Cervical Cancer, Recurrent Cervical Cancer
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04974944
- Testing
- Camrelizumab, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Advanced or Metastatic Gastric Cancer
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT01512745
- Testing
- apatinib
- Where
- 2 sites in China
- Volunteers
- 267 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-squamous Non-small Cell Lung Cancer
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell…
- Trial name
- NCT03127319
- Testing
- apatinib docetaxel zoledronic, docetaxel zoledronic
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Hebei University
Liver Cancer
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
- Trial name
- NCT07587034
- Testing
- HTAC, HAC, TAC
- Volunteers
- 315 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Gastric Cancer
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced…
- Trial name
- NCT03954756
- Testing
- Apatinib and PD1
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital
Ovarian Cancer
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with weekly…
- Trial name
- NCT04000295
- Testing
- Apatinib, Etoposide, Paclitaxel
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.This study was a one-arm, single-center, open…
- Trial name
- NCT03912857
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination…
- Trial name
- NCT05156970
- Testing
- Camrelizumab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Liver Cancer
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Targeted Therapy and a PD-1 Inhibitor in Patients with Postoperative Hepatocellular Carcinoma…
- Trial name
- NCT07790419
- Testing
- HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhai Wenlong